{
  "id": "60273a161cb411341a0000d8",
  "type": "list",
  "question": "Which drugs were investigated in the ALPHEUS trial?",
  "ideal_answer": "ALPHEUS study examined if ticagrelor was superior to clopidogrel in reducing periprocedural myocardial necrosis in stable coronary patients undergoing high-risk elective percutaneous coronary intervention (PCI).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32473356",
    "http://www.ncbi.nlm.nih.gov/pubmed/33202219"
  ],
  "snippets": [
    {
      "text": "METHODS: Assessment of Loading with the P2Y12 inhibitor ticagrelor or clopidogrel to Halt ischemic Events in patients Undergoing elective coronary Stenting (ALPHEUS) (NCT02617290) is an international, multicenter, randomized, parallel-group, open-label study in patients with stable coronary artery disease who are planned for an elective PCI. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32473356",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION: ALPHEUS is the first properly sized trial comparing ticagrelor to clopidogrel in the setting of elective PCI and is especially designed to show a reduction in periprocedural events, a surrogate end point for mortality.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32473356",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33202219",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": ". Eligible patients were randomly assigned (1:1) to either ticagrelor (180 mg loading dose, 90 mg twice daily thereafter for 30 days) or clopidogrel (300-600 mg loading dose, 75 mg daily thereafter for 30 days) by use of an interactive web response system, and stratified by centre. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33202219",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": ".INTERPRETATION: Ticagrelor was not superior to clopidogrel in reducing periprocedural myocardial necrosis after elective PCI and did not cause an increase in major bleeding, but did increase the rate of minor bleeding at 30 days.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33202219",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The aim of the ALPHEUS study was to examine if ticagrelor was superior to clopidogrel in reducing periprocedural myocardial necrosis in stable coronary patients undergoing high-risk elective PCI.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33202219",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "oading with the P2Y12 inhibitor ticagrelor or clopidogrel to Halt ischemic Events in patients Undergoing elective coronary Stenting (ALPHEUS) (NCT02617290) is an international, multicenter, randomized, parallel-group, open-label study in patients with stable coronary artery disease who are planned for an elective PCI. In total, 1,900 patients will be randomized b",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32473356",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The aim of the ALPHEUS study was to examine if ticagrelor was superior to clopidogrel in reducing periprocedural myocardial necrosis in stable coronary patients undergoing high-risk elective PCI.M",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33202219",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " elective PCI/stent. Safety will be evaluated by major bleeding events (Bleeding Academic Research Consortium type 3 or 5) at 48 hours (or discharge if it occurs earlier).CONCLUSION: ALPHEUS is the first properly sized trial comparing ticagrelor to clopidogrel in the setting of elective PCI and is especially designed to show a reduction in periprocedural events, a s",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32473356",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "e patients. Antiplatelet therapy with a potent P2Y12 receptor inhibitor such as ticagrelor may reduce periprocedural ischemic complications while maintaining a similar safety profile as compared with conventional dual antiplatelet therapy by aspirin and clopidogrel in this setting.METHODS: Assessment of Loading with the P2Y12 inhibitor ticagrelor or clopidogrel to Halt ischemic Events in patients Undergoing elective coronary Stenting (ALPHEUS) (NCT02617290) is an international, multicenter, randomized, parallel-group, open-label study in patients with stable coronary artery disease who are planned",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32473356",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "ticagrelor, clopidogrel"
}